Patents by Inventor Nasim Kassam

Nasim Kassam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES WHICH BIND HUMAN CXCR3
    Publication number: 20170081413
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.
    Type: Application
    Filed: May 4, 2016
    Publication date: March 23, 2017
    Inventors: Shixin Qin, Nasim Kassam, Walter Newman
  • ANTIBODIES WHICH BIND HUMAN CXCR3
    Publication number: 20160009808
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.
    Type: Application
    Filed: September 23, 2015
    Publication date: January 14, 2016
    Inventors: Shixin Qin, Nasim Kassam, Walter Newman
  • Antibodies which bind human CXCR3
    Patent number: 9163084
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: October 20, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Shixin Qin, Nasim Kassam, Walter Newman
  • ANTIBODIES WHICH BIND HUMAN CXCR3
    Publication number: 20110280875
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.
    Type: Application
    Filed: June 28, 2011
    Publication date: November 17, 2011
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Shixin Qin, Nasim Kassam, Walter Newman
  • Antibodies which bind human CXCR3
    Patent number: 7994287
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.
    Type: Grant
    Filed: June 23, 2008
    Date of Patent: August 9, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Shixin Qin, Nasim Kassam, Walter Newman
  • Antibodies which bind human CXCR3
    Publication number: 20090285835
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.
    Type: Application
    Filed: June 23, 2008
    Publication date: November 19, 2009
    Inventors: Shixin Qin, Nasim Kassam, Walter Newman
  • Antibodies which bind human CXCR3
    Patent number: 7405275
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.
    Type: Grant
    Filed: September 24, 2004
    Date of Patent: July 29, 2008
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Shixin Qin, Nasim Kassam, Walter Newman
  • Anti-CCR1 antibodies and methods of use thereof
    Patent number: 7232567
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 1 (CCR1) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR1 with a ligand thereof, and to use of the antibodies and fragments in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: April 26, 2004
    Date of Patent: June 19, 2007
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Shixin Qin, Walter Newman, Nasim Kassam
  • Antibodies which bind human CXCR3
    Publication number: 20050112119
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.
    Type: Application
    Filed: September 24, 2004
    Publication date: May 26, 2005
    Inventors: Shixin Qin, Nasim Kassam, Walter Newman
  • Anti-CCR1 antibodies and methods of use therefor
    Publication number: 20040265304
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 1 (CCR1) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR1 with a ligand thereof, and to use of the antibodies and fragments in research, therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: April 26, 2004
    Publication date: December 30, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Shixin Qin, Walter Newman, Nasim Kassam
  • Anti-CCR1 antibodies and methods of use therefor
    Patent number: 6756035
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 1 (CCR1) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR1 with a ligand thereof, and to use of the antibodies and fragments in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: June 29, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Shixin Qin, Walter Newman, Nasim Kassam
  • Methods of use for anti-CCR1 antibodies
    Patent number: 6723570
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 1 (CCR1) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR1 with a ligand thereof, and to use of the antibodies and fragments in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: April 20, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Shixin Qin, Walter Newman, Nasim Kassam
  • Anti-CCR1 antibodies and methods of use therefor
    Publication number: 20020061305
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 1 (CCR1) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR1 with a ligand thereof, and to use of the antibodies and fragments in research, therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: September 21, 2001
    Publication date: May 23, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Shixin Qin, Walter Newman, Nasim Kassam
  • Anti-CCR1 antibodies and methods of use therefor
    Publication number: 20020037539
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 1 (CCR1) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR1 with a ligand thereof, and to use of the antibodies and fragments in research, therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: September 21, 2001
    Publication date: March 28, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Shixin Qin, Walter Newman, Nasim Kassam
  • Anti-CCR1 antibodies and methods of use therefor
    Patent number: 6329510
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 1 (CCR1) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR1 with a ligand thereof, and to use of the antibodies and fragments in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: January 29, 1999
    Date of Patent: December 11, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Shixin Qin, Walter Newman, Nasim Kassam